US › Healthcare

Redhill Biopharma Ltd (RDHL)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$0.65-0.35%

Last close · 2026-08-04

Latest quarter · ended 2025-06-30

Revenue

$2.0M

Revenue YoY

+58.6%

Net profit

$-2.1M

Profit YoY

-33.8%

EPS

$0.00

EPS estimate

$0.00

Net margin

-101.3%

Key statistics

Market cap

$4.0M

P/E

0.0

Forward P/E

1,428.6

P/B

0.93

Book value

$0.84

EPS (TTM)

$0.00

52-week high

$2.79

52-week low

$0.63

50-day MA

$0.83

200-day MA

$1.03

Beta

4.97

Analyst view

Analysts rate Redhill Biopharma Ltd a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $19,000.00.

Shareholding

Institutions

8.53%

Largest institutional holders

Fund	Stake
Yorkville Advisors Global, LP	5.77%
Gagnon Securities LLC	1.45%
Citadel Advisors Llc	0.34%
XTX Topco Ltd	0.25%
StoneX Group Inc	0.24%
TWO SIGMA SECURITIES, LLC	0.21%
GAMMA Investing LLC	0.11%
Rhumbline Advisers	0.08%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Redhill Biopharma Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.